SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol
Jens Toft Eschen, Line Louise Jensen, David Hausmann, Allice Nyborg Rosenkrans Lind, Slavka Lukacova, Joachim Weischenfeldt, Ulrik Lassen, Manfred Westphal, Frank Winkler, Ulf Simonsen, Anders Rosendal Korshoej · 2026
Read SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed glioblastoma: a trial protocol by Jens Toft Eschen, Line Louise Jensen, David Hausmann, Allice Nyborg Rosenkrans Lind, Slavka Lukacova, Joachim Weischenfeldt, Ulrik Lassen, Manfred Westphal, Frank Winkler, Ulf Simonsen, Anders Rosendal Korshoej (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13196081.txt.
Description
BackgroundGlioblastoma is the most aggressive primary brain tumour in adults with a dismal prognosis and median overall survival of 12–14 months despite standard therapy. Novel discoveries in Cancer Neuroscience have revealed excitatory neuron-to-tumour synapses that drive glioma proliferation and invasion via AMPA-receptor activation, and vital tumour-autonomous calcium signalling mediated by KCa3.1 channels that sustain cancer cell network- and therapy resistance.
Catalog record
| CREATOR | Jens Toft Eschen, Line Louise Jensen, David Hausmann, Allice Nyborg Rosenkrans Lind, Slavka Lukacova, Joachim Weischenfeldt, Ulrik Lassen, Manfred Westphal, Frank Winkler, Ulf Simonsen, Anders Rosendal Korshoej |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |